You searched for: indolent (Engelska - Maltesiska)

indolent non hodgkin lymphoma including follicular lymphoma
limfoma mhux ta’ hodgkin indolenti inkluż limfoma follikulari

the applicant should submit the final study report for phase 2 study 101-09 to evaluate the efficacy and safety of idelalisib in subjects with indolent b-cell nhl refractory to rituximab and alkylating agents.
l-applikant għandu jissottometti r-rapport finali tal-istudju għal studju ta’ fażi 2 101-09, biex jiġu evalwati l-effikaċja u s-sigurtà ta’ idelalisib f’individwi b’nhl indolenti ta’ ċelluli b reżistenti għal rituximab u sustanzi alkilatiċi.

the adverse drug reactions (adrs) described in this section were identified during treatment and follow up in the two pivotal clinical studies, bo21004/cll11, n=781, and gao4753g, n=396 patients, in previously untreated cll patients, and indolent non hodgkin lymphoma (inhl) patients (81.1% of the patients had fl) who had no response to or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.
ir-reazzjonijiet avversi tal-mediċina (adrs - adverse drug reactions) deskritti f’ din is-sezzjoni kienu identifikati waqt il-kura u fil-visti ta’ wara fiż-żewġ studji kliniċi pivitali, bo21004/cll11, n=781, u gao4753g, n=396 pazjent, f’pazjenti b’cll li ma kinux ittrattati qabel, u f’pazjenti b’limfoma mhux ta’ hodgkin indolenti (inhl - indolent non hodgkin lymphoma) (81.1% tal-pazjenti kellhom fl) li ma kellhom l-ebda rispons għal jew li kellhom progressjoni matul jew sa 6 xhur wara trattament b’rituximab jew b’kors li fih rituximab.